Balloon dilatation for bronchial stenosis in Endobronchial Tuberculosis.
10.4046/trd.1996.43.5.701
- Author:
Joon Sang OHN
1
;
Young Sil LEE
;
Sang Won YOON
;
Hyung Dae SON
;
Chang Seon KIM
;
Jee Young SEO
;
Mi Ran PARK
;
Nam Soo RHEU
;
Dong Ill CHO
;
Byung Kook KWAK
Author Information
1. Department of Chest Medicine, National Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Bronchi;
Stenosis;
Endobronchial Tuberculosis;
Balloon dilatation;
PFT(Pulmonary Function Test)
- MeSH:
Airway Obstruction;
Anesthesia, Local;
Bronchi;
Constriction, Pathologic*;
Cough;
Cryotherapy;
Dilatation*;
Dyspnea;
Female;
Fever;
Humans;
Leukocytosis;
Mediastinal Emphysema;
Mediastinitis;
Pneumothorax;
Respiratory Sounds;
Sputum;
Thorax;
Tuberculosis*
- From:Tuberculosis and Respiratory Diseases
1996;43(5):701-708
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: To evaluate the effect of the balloon dilatation in tuberculous bronchial stenosis, we performed balloon dilatation in 13 cases which had airway obstruction in main bronchus with the impairment of pulmonary function. MATERIAL AND METHODS: Thirteen women with tuberculous bronchial stenosis(9cases: left main bronchus, 4 cases: right main bronchus) underwent fluoroscopically guided balloon dilatation under the local anesthesia. Among the these patient, 9 cases were active endobronchial tuberculosis, and 4 cases were inactive. Immediate and long term follow-up(average 15.6months) assessments were done focused on change on PFT. The increase of FVC or FEV1 more than 15% after the procedure was considered effective. Complications after dilatation were evaluated in all patients. RESULT: 1) There were an decrease of self-audible wheezing in 75%(6/8), improvement of dyspnea in 62.5%(5/8), improvement of cough and expectoration in 50%(3/6), and improvement of chest discomfort in 50%(l/2). 2) Significant improvement of PFT was noted in 42.9%(3/7) of which respiratory symptoms duration was below 6 months. But, significant improvement of PFT was noted in only 25% (1/4) of which respiratory symptoms duration was above 12 months. 3) Active stage was 69.2%(9/13) and inactive was 30.8%(4/13). There was an significant improvement of PFT in 44.4%(4/9) of active stage, but, only 25%(l/4) of inactive stage was improved. 4) In 61.5%(8/13), FVC and FEV1 were increased to 35.5%, and 22.2% at post-dilatation 7 days. After 1 month later, FVC and FEV1 were increased to 54.7%, and 31.8% in 5 cases(38.5%). 4 cases in which long-term follow-up(average 19.8months) was possible the improvement of FVC, and FEV1 were 30.5%, and 10.1%. . 5) Just after balloon dilatation therapy, transient leukocytosis or fever was noted in 30.8%(4/13), and blood-tinged sputum was noted in 30.8%(4/13). However, serious complication, such as pneumothorax, pneumomediastinum or mediastinitis, was not noted. CONCLUSION: We conclude that tuberculous bronchial stenosis, which is on active stage, and short dulation of respiratory symptoms was more effective on balloon dilatation than inactive stage or long duration of respiratory symptoms. Furthermore, balloon dilatation is easier, much less invasive and expensive than open surgery, and cryotherapy or photoresection. Because of these advantage, we think that balloon dilatation could be the first choice for treating bronchial stenosis and could be done at first in early stage if unresponsiveness with steroid therapy is observed.
